JP2004535402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004535402A5 JP2004535402A5 JP2002590923A JP2002590923A JP2004535402A5 JP 2004535402 A5 JP2004535402 A5 JP 2004535402A5 JP 2002590923 A JP2002590923 A JP 2002590923A JP 2002590923 A JP2002590923 A JP 2002590923A JP 2004535402 A5 JP2004535402 A5 JP 2004535402A5
- Authority
- JP
- Japan
- Prior art keywords
- soluble
- atcc
- antibody
- reacts
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100032937 CD40 ligand Human genes 0.000 description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 5
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 2
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29340201P | 2001-05-23 | 2001-05-23 | |
| US60/293,402 | 2001-05-23 | ||
| PCT/US2002/016708 WO2002094202A2 (en) | 2001-05-23 | 2002-05-23 | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004535402A JP2004535402A (ja) | 2004-11-25 |
| JP2004535402A5 true JP2004535402A5 (cg-RX-API-DMAC10.html) | 2009-02-05 |
| JP4837880B2 JP4837880B2 (ja) | 2011-12-14 |
Family
ID=23128937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002590923A Expired - Fee Related JP4837880B2 (ja) | 2001-05-23 | 2002-05-23 | 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法 |
Country Status (17)
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887471B1 (en) * | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ATE219376T1 (de) * | 1996-03-20 | 2002-07-15 | Bristol Myers Squibb Co | Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| MXPA02012157A (es) * | 2000-06-09 | 2003-06-06 | Bristol Myers Squibb Co | Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos. |
| CA2630062C (en) * | 2000-07-03 | 2014-10-14 | Bristol-Myers Squibb Company | Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| MXPA03006699A (es) * | 2001-01-26 | 2004-05-31 | Univ Emory | Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias. |
| ATE390931T1 (de) * | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| TWI328614B (en) * | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| EP1575998A4 (en) * | 2002-12-23 | 2007-07-25 | Bristol Myers Squibb Co | PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION |
| NZ545314A (en) * | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| EP1658096A1 (en) * | 2003-08-25 | 2006-05-24 | PanGenetics B.V. | Method of inducing immune tolerance |
| PL1868635T3 (pl) | 2005-04-06 | 2017-10-31 | Bristol Myers Squibb Co | Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4 |
| US9457070B2 (en) | 2005-06-07 | 2016-10-04 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease |
| CA2654446C (en) | 2005-06-07 | 2014-02-25 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
| US8715649B2 (en) * | 2005-06-07 | 2014-05-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
| AU2006292827B2 (en) * | 2005-08-09 | 2013-02-14 | Revivicor, Inc. | Transgenic ungulates expressing CTLA4-IG and uses thereof |
| US20070087029A1 (en) * | 2005-10-14 | 2007-04-19 | Pakala Syamasundar V | Localized delivery to the lymphatic system |
| PT2253644E (pt) | 2005-12-20 | 2014-01-23 | Bristol Myers Squibb Co | Composições e métodos para a produção de uma composição |
| AR058568A1 (es) * | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
| US20090029904A1 (en) * | 2006-07-21 | 2009-01-29 | Sean Oldham | Compositions and methods for treatment of insulin-resistance diseases |
| WO2008014035A2 (en) * | 2006-07-25 | 2008-01-31 | The Regents Of The University Of California | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
| CN104177464B (zh) * | 2006-08-18 | 2017-04-12 | 阿哥斯医疗公司 | Cd83在联合治疗中的用途 |
| GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| CA2703263C (en) * | 2007-11-01 | 2014-03-18 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
| US20090191608A1 (en) * | 2008-01-22 | 2009-07-30 | Baylor Research Institute | Pancreatic Islet Cell Preparation and Transplantation |
| US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD |
| AU2009298131B2 (en) | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| WO2010049935A1 (en) * | 2008-10-30 | 2010-05-06 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| CA2937492C (en) | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
| US8758323B2 (en) | 2009-07-30 | 2014-06-24 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| KR20180036810A (ko) * | 2009-08-14 | 2018-04-09 | 레비비코르 인코포레이션 | 당뇨병 치료를 위한 복수 형질전환 돼지 |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
| WO2011113019A2 (en) | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| WO2011146395A2 (en) | 2010-05-17 | 2011-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade |
| ES2589678T3 (es) | 2010-09-08 | 2016-11-15 | Yeda Research And Development Co. Ltd. | Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma |
| EP2614083A2 (en) | 2010-09-08 | 2013-07-17 | Yeda Research and Development Co. Ltd | An immunosuppressive drug combination for a stable and long term engraftment |
| EP2675901B1 (en) | 2011-02-14 | 2018-05-30 | Revivicor, Inc. | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
| EP3628327A1 (en) | 2011-06-24 | 2020-04-01 | The Regents of the University of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| SG11201400513PA (en) | 2011-09-08 | 2014-06-27 | Yeda Res & Dev | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| AU2013284460A1 (en) * | 2012-06-27 | 2015-01-29 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
| US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
| US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| EA201591883A1 (ru) * | 2013-03-28 | 2016-02-29 | Бристол-Майерс Сквибб Компани | Способы выявления пациентов, подверженных риску отторжения, резистентного к блокаде костимуляции |
| WO2014182601A1 (en) * | 2013-05-08 | 2014-11-13 | Children's Medical Center Corporation | A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis) |
| ES2769778T3 (es) * | 2013-12-13 | 2020-06-29 | Swedish Stromabio Ab | Composiciones inmunomoduladoras |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| AU2016291825B2 (en) | 2015-07-16 | 2022-08-11 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory T cells and use of same in immunotherapy |
| US11260027B2 (en) | 2015-07-29 | 2022-03-01 | Musc Foundation For Research Development | Donor organ pre-treatment formulation |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| IT201800000534A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
| GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| ES3064681T3 (en) | 2017-01-18 | 2026-04-28 | Yeda Res & Dev | Genetically modified veto cells and use of same in immunotherapy |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| FR3090320B1 (fr) * | 2018-12-19 | 2023-03-03 | Karim Bouzakri | Utilisation de la decorine dans le traitement du diabete |
| WO2020186247A1 (en) | 2019-03-13 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| CN115089718B (zh) * | 2021-11-30 | 2024-05-28 | 杭州瑞普晨创科技有限公司 | 用于异种移植的免疫抑制剂组合和免疫抑制方法 |
| WO2025235670A1 (en) * | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| CA2003455C (en) | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
| US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) * | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) * | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US7070776B1 (en) | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| DE69226871T3 (de) * | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| US5958403A (en) * | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
| CA2133075A1 (en) | 1992-04-07 | 1993-10-14 | Craig B. Thompson | CD28 Pathway Immunoregulation |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| CA2164226C (en) | 1993-06-04 | 2011-02-08 | Carl H. June | Methods for selectively stimulating proliferation of t cells |
| AU7107794A (en) | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
| CN1127351C (zh) | 1993-09-02 | 2003-11-12 | 达特茅斯学院理事 | 诱导抗原特异性ｔ细胞耐受的方法 |
| US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| WO1995033823A1 (en) | 1994-06-03 | 1995-12-14 | The United States Of America, Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of t cells |
| CA2191733A1 (en) | 1994-06-07 | 1995-12-21 | Daniel A. Vallera | Methods for inhibiting antigen specific t cell responses |
| AU4158396A (en) | 1994-11-10 | 1996-06-06 | Dana-Farber Cancer Institute | Methods for inhibiting graft versus host disease in bone marrow transplantation |
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| GB9506844D0 (en) * | 1995-04-03 | 1995-05-24 | Armitage Ian M | Pharmaceutical microencapsulation |
| US5993800A (en) * | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US7041634B2 (en) * | 1995-09-27 | 2006-05-09 | Emory University | Method of inhibiting immune system destruction of transplanted viable cells |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| ATE219376T1 (de) * | 1996-03-20 | 2002-07-15 | Bristol Myers Squibb Co | Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung |
| KR19980066046A (ko) | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| EP1009432A4 (en) | 1997-06-11 | 2004-07-07 | Us Navy | COMPOSITIONS AND METHODS FOR THE INHIBITION OF TRANSPLANT REPOSITION AND OTHERS AGAINST THE IMMUNE RESPONSE GIVEN BY T-LYMPHOCYTES |
| IL137614A0 (en) | 1998-02-04 | 2001-07-24 | Gen Hospital Corp | An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance |
| IL126681A0 (en) | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| WO2001090122A2 (en) | 2000-05-23 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ctla4 gene |
| TWI314933B (en) | 2000-05-26 | 2009-09-21 | Bristol Myers Squibb Compan | Soluble ctla4 mutant molecules and uses thereof |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| AU2006203199B2 (en) * | 2000-05-26 | 2009-02-12 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| MXPA02012157A (es) * | 2000-06-09 | 2003-06-06 | Bristol Myers Squibb Co | Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos. |
| US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| CA2630062C (en) | 2000-07-03 | 2014-10-14 | Bristol-Myers Squibb Company | Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| MXPA03006699A (es) * | 2001-01-26 | 2004-05-31 | Univ Emory | Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias. |
| US20030031652A1 (en) | 2001-04-16 | 2003-02-13 | Bernhard Hering | Systems and methods for inducing mixed chimerism |
| ATE390931T1 (de) * | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| EP1575998A4 (en) | 2002-12-23 | 2007-07-25 | Bristol Myers Squibb Co | PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION |
| TWI328614B (en) | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| NZ545314A (en) | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
-
2002
- 2002-05-23 AT AT02734556T patent/ATE390931T1/de active
- 2002-05-23 CA CA2447921A patent/CA2447921C/en not_active Expired - Fee Related
- 2002-05-23 PL PL364578A patent/PL204899B1/pl unknown
- 2002-05-23 WO PCT/US2002/016708 patent/WO2002094202A2/en not_active Ceased
- 2002-05-23 ES ES02734556T patent/ES2302811T3/es not_active Expired - Lifetime
- 2002-05-23 MX MXPA03010568A patent/MXPA03010568A/es active IP Right Grant
- 2002-05-23 DE DE60225914T patent/DE60225914T2/de not_active Expired - Lifetime
- 2002-05-23 DK DK02734556T patent/DK1397153T3/da active
- 2002-05-23 AU AU2002305716A patent/AU2002305716B2/en not_active Ceased
- 2002-05-23 EP EP02734556A patent/EP1397153B1/en not_active Expired - Lifetime
- 2002-05-23 US US10/155,514 patent/US7304033B2/en not_active Expired - Lifetime
- 2002-05-23 JP JP2002590923A patent/JP4837880B2/ja not_active Expired - Fee Related
- 2002-05-23 PT PT02734556T patent/PT1397153E/pt unknown
- 2002-05-23 HU HU0401590A patent/HU229680B1/hu not_active IP Right Cessation
- 2002-05-23 CZ CZ2003-3188A patent/CZ305380B6/cs not_active IP Right Cessation
-
2003
- 2003-11-21 NO NO20035176A patent/NO332465B1/no not_active IP Right Cessation
-
2007
- 2007-10-29 US US11/978,701 patent/US7829534B2/en not_active Expired - Lifetime
-
2008
- 2008-06-09 CY CY20081100608T patent/CY1108127T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fernandez-Poma et al. | Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy | |
| Dreier et al. | Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody | |
| Raitakari et al. | T‐cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells | |
| Takamatsu et al. | A sub-population of circulating porcine γδ T cells can act as professional antigen presenting cells | |
| ATE477276T1 (de) | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen | |
| Eyrich et al. | Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia–a prospective study of 20 paediatric patients | |
| MX9602879A (es) | Moleculas mutantes de ctla4 y usos de las mismas. | |
| Spiotto et al. | Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells | |
| Prince et al. | Phenotypic comparison of the three populations of human lymphocytes defined by CD45RO and CD45RA expression | |
| JP2015071598A5 (cg-RX-API-DMAC10.html) | ||
| DK1516881T3 (da) | Sammensætning og fremgangsmåde til modulering af dendritcelle-T-celle-interaktioner | |
| EP0671927A4 (en) | HUMAN, NEUTRALIZING, MONOCLONAL ANTIBODIES AGAINST THE RESPIRATORY SYNCYTIAL VIRU. | |
| WO2005000901A3 (en) | Cd20-specific antibodies and methods of employing same | |
| RU2012152828A (ru) | Опосредованное иммунорецепторами дендритных клеток (dcir) перекрестное примирование cd8+ т клеток человека | |
| Verma et al. | Immunotherapy in extensive small cell lung cancer | |
| KR910014130A (ko) | 안티-cd28 항체를 사용하여 임파구의 세포붕해활성을 활성화 시키는 방법 | |
| Wang et al. | Can the dual-functional capability of CIK cells be used to improve antitumor effects? | |
| Merlo et al. | CD85/LIR-1/ILT2 and CD152 (cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the cytolytic activity of human CD4+ T-cell clones specific for Mycobacterium tuberculosis | |
| Van de Griend et al. | Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies. | |
| Branco et al. | Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells | |
| Flohr et al. | Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL | |
| Phillips et al. | Evidence that the T cell antigen receptor may not be involved in cytotoxicity mediated by gamma/delta and alpha/beta thymic cell lines. | |
| CA2137638A1 (en) | Anti Gangliosides Monoclonal Antibodies and Their Use in the Specific Active Immunotherapy of Malignant Tumors | |
| Van Den Broeke et al. | Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors | |
| Kanagawa | Antibody-mediated activation of T cell clones as a method for screening hybridomas producing antibodies to the T cell receptor |